Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…cluded patients who received at least one ICI (e.g., nivolumab, pembrolizumab); Cohort 2 included those who did not. Propensity score matchin…
…on E, Sondak VK, Ribas A. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023 Mar 2;388(9):813-823.B…
…(42.6%) did not. The most frequently administered regimens were ipilimumab, nivolumab, and pembrolizumab, with or without platinum-based c…
…ipilimumab/chemotherapy), against KEYNOTE-189, and KEYNOTE-407 (pembrolizumab/chemotherapy). We analyzed both the progression free survival (…
…pan-tumor cutoff of 10 mutations (mt)/MB gained FDA approval of pembrolizumab although optimal cutoffs are not clearly defined. Here, we asse…
…O Annual Meeting, the KEYNOTE-564 trial confirmed that adjuvant pembrolizumab significantly improves disease-free survival (DFS) and overall …
…berman M, Kato T, Tsuboi M, Lee SH, Gao S, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023 …
…urvival (p < 0.05). In metastatic colorectal cancer, first-line pembrolizumab yielded superior overall survival in microsatellite instability…
…d P, Skidmore ZL, Nussenbaum B, et al. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated …
…ctive cohort of NPC patients receiving induction immunotherapy (pembrolizumab) and concurrent chemoirradiation, we analysed the plasma EBV DN…
…nt with anal cancer previously treated with 5 agents, including nivolumab. The duration of the complete responses is 8 months and 9 month…
…types were urothelial (n=307; 53.9%) and breast (n=125; 21.9%). Pembrolizumab (n=386; 67.7%) and enfortumab vedotin (n=291; 51.1%) were the m…